| Item type |
Journal Article(1) |
| 公開日 |
2021-08-24 |
| タイトル |
|
|
タイトル |
Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
Hiwasa, Takaki
Wang, Hao
Goto, Ken-ichiro
Mine, Seiichiro
Machida, Toshio
Kobayashi, Eiichi
Yoshida, Yoichi
Adachi, Akihiko
Matsutani, Tomoo
Sata, Mizuki
山岸, 良匡
Iso, Hiroyasu
Sawada, Norie
Tsugane, Shoichiro
Kunimatsu, Mitoshi
Kamitsukasa, Ikuo
Mori, Masahiro
Sugimoto, Kazuo
Uzawa, Akiyuki
Muto, Mayumi
Kuwabara, Satoshi
Kobayashi, Yoshio
Ohno, Mikiko
Nishi, Eiichiro
Hattori, Akiko
Yamamoto, Masashi
Maezawa, Yoshiro
Kobayashi, Kazuki
Ishibashi, Ryoichi
Takemoto, Minoru
Yokote, Koutaro
Takizawa, Hirotaka
Kishimoto, Takashi
Matsushita, Kazuyuki
Kobayashi, Sohei
Nomura, Fumio
Arasawa, Takahiro
Kagaya, Akiko
Maruyama, Tetsuro
Matsubara, Hisahiro
Tomiita, Minako
Hamanaka, Shinsaku
Imai, Yushi
Nakagawa, Tomoo
Kato, Naoya
Terada, Jiro
Matsumura, Takuma
Katsumata, Yusuke
Naito, Akira
Tanabe, Nobuhiro
Sakao, Seiichiro
Tatsumi, Koichiro
Ito, Masaaki
Shiratori, Fumiaki
Sumazaki, Makoto
Yajima, Satoshi
Shimada, Hideaki
Shirouzu, Mikako
Yokoyama, Shigeyuki
Kudo, Takashi
Doi, Hirofumi
Iwase, Katsuro
Ashino, Hiromi
Li, Shu-Yang
Kubota, Masaaki
Tomiyoshi, Go
Shinmen, Natsuko
Nakamura, Rika
Kuroda, Hideyuki
Iwadate, Yasuo
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background
Acute ischemic stroke (AIS) is a serious cause of mortality and disability. AIS is a serious cause of mortality and disability. Early diagnosis of atherosclerosis, which is the major cause of AIS, allows therapeutic intervention before the onset, leading to prevention of AIS.
Methods
Serological identification by cDNA expression cDNA libraries and the protein array method were used for the screening of antigens recognized by serum IgG antibodies in patients with atherosclerosis. Recombinant proteins or synthetic peptides derived from candidate antigens were used as antigens to compare serum IgG levels between healthy donors (HDs) and patients with atherosclerosis-related disease using the amplified luminescent proximity homogeneous assay-linked immunosorbent assay.
Results
The first screening using the protein array method identified death-inducer obliterator 1 (DIDO1), forkhead box J2 (FOXJ2), and cleavage and polyadenylation specificity factor (CPSF2) as the target antigens of serum IgG antibodies in patients with AIS. Then, we prepared various antigens including glutathione S-transferase-fused DIDO1 protein as well as peptides of the amino acids 297–311 of DIDO1, 426–440 of FOXJ2, and 607–621 of CPSF2 to examine serum antibody levels. Compared with HDs, a significant increase in antibody levels of the DIDO1 protein and peptide in patients with AIS, transient ischemic attack (TIA), and chronic kidney disease (CKD) but not in those with acute myocardial infarction and diabetes mellitus (DM). Serum anti-FOXJ2 antibody levels were elevated in most patients with atherosclerosis-related diseases, whereas serum anti-CPSF2 antibody levels were associated with AIS, TIA, and DM. Receiver operating characteristic curves showed that serum DIDO1 antibody levels were highly associated with CKD, and correlation analysis revealed that serum anti-FOXJ2 antibody levels were associated with hypertension. A prospective case–control study on ischemic stroke verified that the serum antibody levels of the DIDO1 protein and DIDO1, FOXJ2, and CPSF2 peptides showed significantly higher odds ratios with a risk of AIS in patients with the highest quartile than in those with the lowest quartile, indicating that these antibody markers are useful as risk factors for AIS.
Conclusions
Serum antibody levels of DIDO1, FOXJ2, and CPSF2 are useful in predicting the onset of atherosclerosis-related AIS caused by kidney failure, hypertension, and DM, respectively. |
|
言語 |
en |
| 書誌情報 |
en : BMC medicine
巻 19,
p. 131,
発行日 2021-06
|
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1741-7015 |
| NCID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12035245 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1186/s12916-021-02001-9 |
| PMID |
|
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
34103026 |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 出版者 |
|
|
出版者 |
BioMed Central |
|
言語 |
en |
BMCMedicine_19-131.pdf (1.5 MB)
.png)
